Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perindopril
Drug ID BADD_D01739
Description Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Indications and Usage For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Marketing Status approved
ATC Code C09AA04
DrugBank ID DB00790
KEGG ID D03753
MeSH ID D020913
PubChem ID 107807
TTD Drug ID D03KYG
NDC Product Code 65977-0019
UNII Y5GMK36KGY
Synonyms Perindopril | Pirindopril | S-9490 | S 9490 | S9490 | S 9490-3 | S 9490 3 | S 94903 | Perindopril Erbumine | Erbumine, Perindopril | Perstarium
Chemical Information
Molecular Formula C19H32N2O5
CAS Registry Number 82834-16-0
SMILES CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Seasonal allergy10.01.04.001; 06.04.01.013; 22.04.04.008--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Male sexual dysfunction21.03.02.012; 19.08.05.003--Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Tinea infection23.11.03.011; 11.03.08.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene